Voss Capital’s Regenxbio RGNX Stock Holding History

Voss Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-295,787	Closed	-$2.48M	–	68
2026 Q1	$2.48M	Buy	295,787 +787	+0.3%	+$8.27K	0.13%	43
2025 Q4	$4.25M	Sell	295,000 -205,000	-41%	-$2.56M	0.2%	41
2025 Q3	$4.83M	Sell	500,000 -75,000	-13%	-$663K	0.24%	39
2025 Q2	$4.72M	Buy	575,000 +185,000	+47%	+$1.55M	0.33%	33
2025 Q1	$2.79M	Buy	390,000 +57,186	+17%	+$425K	0.21%	42
2024 Q4	$2.57M	Buy	+332,814	New	+$3.12M	0.19%	37

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Voss Capital's RGNX Position: Q2 2026 in Review

Voss Capital sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 295,787 shares — an estimated $2.48M sold.

Voss Capital first reported a position in RGNX in Q4 2024 and held it in 6 quarters. The position peaked at $4.83M in Q3 2025. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Voss Capital reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
Voss Capital sold 295,787 Regenxbio shares in Q2 2026, an estimated $2.48M.
Voss Capital first reported a position in Regenxbio in Q4 2024 and held it in 6 quarters.
Voss Capital's Regenxbio position peaked at $4.83M in Q3 2025.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Voss Capital's 13F filing for Q2 2026, filed 14 Aug 2026.